CORRIXR THERAPEUTICS
Live / Applied — Revived — awaiting further action (as of 26 Nov 2025)
What this means for you
Not registered yet, but its 31 Mar 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97340109
- Mark type
- Stylized text
- Filed
- 31 Mar 2022
- Published for opposition
- 15 Aug 2023
- Attorney of record
- Gregory S. Bernabeo
Goods and services
- Class 042 — Scientific and technological services: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development; research and development of therapeutics pharmaceuticals using gene editing; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy
Owner
- CorriXR Therapeutics, Inc., Newark, DE, US
- CorriXR Therapeutics, Inc., Wilmington, DE, US
Prosecution history
- 26 Nov 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 26 Nov 2025 — NOTICE OF REVIVAL - E-MAILED
- 26 Nov 2025 — PETITION TO REVIVE-GRANTED
- 26 Nov 2025 — TEAS PETITION TO REVIVE RECEIVED
- 10 Nov 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 10 Nov 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 09 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Apr 2025 — SOU EXTENSION 3 GRANTED
- 09 Apr 2025 — SOU EXTENSION 3 FILED
- 08 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Oct 2024 — SOU EXTENSION 2 GRANTED
- 07 Oct 2024 — SOU EXTENSION 2 FILED
- 07 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 16 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED